Equity Overview
Price & Market Data
Price: $0.634
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $75,916,912
Volume: 0
Performance Metrics
1 Week: 6.84%
1 Month: -1.38%
3 Months: 1.65%
6 Months: 47.83%
1 Year: -40.73%
YTD: -20.15%
Company Details
Employees: 22
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.